Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Refractory Bacteria Respond to Fecal Transplant

By HospiMedica International staff writers
Posted on 17 Nov 2011
Transplanting fecal matter with healthy bacteria into patients with refractory Clostridium difficile infections can lead to quick relief, according to a new study.

Researchers at Integris Baptist Medical Center (Oklahoma City, OK, USA) and Montefiore Medical Center (New York, NY, USA;) conducted a study that included 77 patients (mean age 65, 73% women) who underwent a colonoscopic fecal-microbiota transplant (FMT) at least three months previously for recurrent C. More...
difficile infection; 31 of the patients were hospitalized, homebound, or in a skilled nursing facility at the time the procedure was performed. The patients subsequently answered a 36-item questionnaire about the results of the transplant.

The researchers found that FMT was successful in 70 out of 77 patients (91%) who were on average elderly, debilitated, and had undergone multiple failed treatments, including antibiotic and probiotic therapies. The average duration of illness for these patients was 11 months, but after the procedure patients continued to improve and did not have a recurrence of C. difficile infection during the follow-up period. In six of the remaining seven patients, a single two-week course of vancomycin or a two-week vancomycin course plus one further FMT resulted in a 98% cure rate. The study was presented at the annual meeting of the American College of Gastroenterology, held during October 2011 in Washington DC (USA).

“Patients with recurrent C. difficile infection had a totally different population in their stool than normal people, characterized by a marked decrease in the diversity of species present,” said lead author and study presenter Mark Mellow, MD, of the Integris Baptist Medical Center. “Therefore, it would make sense that if you performed a massive bacterial replacement, that might very well reverse that condition and allow for a cure in people who were otherwise not curable.”

Clostridium difficile is a major cause of morbidity and increasing health care costs among hospitalized patients, causing infections that lead to diarrhea and is most often related to antibiotic use during medical treatment. C. difficile is especially dangerous for patients with weakened immune systems such as the elderly and those with Inflammatory Bowel Disease (IBD). Therapies for this difficult-to-treat subpopulation include antibiotics, probiotics, toxin-binding medications, active vaccination, intravenous immunoglobon, and FMT.

Related Links:

Integris Baptist Medical Center
Montefiore Medical Center




Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.